NWMG
VRTX icon

National Wealth Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

National Wealth Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-902
Closed -$403K – 244
2026
Q1 		$403K Sell
902
-627
-41% -$292K 0.15% 137
2025
Q4 		$693K Buy
+1,529
New +$659K 0.24% 98
2023
Q2 		– Sell
-1,063
Closed -$369K – 172
2023
Q1 		$369K Buy
+1,063
New +$319K 0.42% 77

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

National Wealth Management Group's VRTX Position: Q2 2026 in Review

National Wealth Management Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 902 shares — an estimated $403K sold.

National Wealth Management Group first reported a position in VRTX in Q1 2023 and held it in 3 quarters. The position peaked at $693K in Q4 2025. 368 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • National Wealth Management Group reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • National Wealth Management Group sold 902 Vertex Pharmaceuticals shares in Q2 2026, an estimated $403K.
  • National Wealth Management Group first reported a position in Vertex Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • National Wealth Management Group's Vertex Pharmaceuticals position peaked at $693K in Q4 2025.
  • 368 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on National Wealth Management Group's 13F filing for Q2 2026, filed 14 Jul 2026.